| Literature DB >> 20964352 |
Mahaveer Swaroop Bhojani1, Marcian Van Dort, Alnawaz Rehemtulla, Brian D Ross.
Abstract
The past decade has seen momentous development in brain cancer research in terms of novel imaging-assisted surgeries, molecularly targeted drug-based treatment regimens or adjuvant therapies and in our understanding of molecular footprints of initiation and progression of malignancy. However, mortality due to brain cancer has essentially remained unchanged in the last three decades. Thus, paradigm-changing diagnostic and therapeutic reagents are urgently needed. Nanotheranostic platforms are powerful tools for imaging and treatment of cancer. Multifunctionality of these nanovehicles offers a number of advantages over conventional agents. These include targeting to a diseased site thereby minimizing systemic toxicity, the ability to solubilize hydrophobic or labile drugs leading to improved pharmacokinetics and their potential to image, treat and predict therapeutic response. In this article, we will discuss the application of newer theranostic nanoparticles in targeted brain cancer imaging and treatment.Entities:
Mesh:
Year: 2010 PMID: 20964352 PMCID: PMC3291122 DOI: 10.1021/mp100298r
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939